Press Releases

March 11 2014

BIO commended the Centers for Medicare & Medicaid Services (CMS) for announcing their...

February 12 2014

Bill would spur capital formation for small public companies

October 28 2013

BIO responds to a Senators letter to FDA Commissioner Margaret Hamburg, regarding naming...

July 29 2013

BIO released a statement in support of the FDA Safety Over Sequestration Act (H.R. 2725), which...

June 20 2013

BIO applauds Sens. Max Baucus (D-MT) and Orrin Hatch (R-UT) and Reps. Jim Gerlach (R-PA) and...

May 16 2013

H.R. 701 sets a deadline to complete rule-making on Regulation A reforms.

May 15 2013

H.R. 1952 will stimulate trading for small public companies.

April 16 2013

Bill would allow emerging biotech companies to maintain a working relationship with their...

March 5 2013

On March 4, 2013, the U.S. House of Representatives passed PAHPRA by a vote of 370-28.

February 28 2013

BIO lauds the Senate for passing H.R. 307, the Pandemic and All-Hazards Preparedness...

September 25 2012

Bill would stimulate capital formation for small biotech companies.

April 17 2012

The Biotechnology Industry Organization (BIO) submitted comments yesterday to the U.S. Food...

March 27 2012

The JOBS Act will incentivize and encourage capital formation for growing companies, and...

March 6 2012

OncoMed Pharmaceuticals SVP/CFO provided testimony today on behalf of BIO at a Senate...

February 15 2012

The bill will modernize the FDA and accelerate patient access to cures and new treatments.

January 25 2012

BIO calls on the administration and Congress to embrace proposals to Unleash the Promise of...

December 15 2011

FDA:  GE salmon will not have significant impact on the...

December 13 2011

Small Business Innovation Research (SBIR) grants provide critical funding for the development...

October 13 2011

BIO President and CEO Jim Greenwood released the following statement on the Obama...

September 16 2011

BIO President and CEO Jim Greenwood released the following statement on President Obama's...

September 9 2011

BIO President and CEO Jim Greenwood released the following statement on President Obama’...

September 8 2011

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

August 3 2011

Animal Agriculture Coalition Members denounce political interference in FDA process.

June 29 2011

“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease...

May 26 2011

Representatives of the bioscience industry testified before the U.S. Congress Joint Economic...

May 26 2011

BIO thanks Sens. Patty Murray (D-Wash.) and Maria Cantwell (D-Wash.) for introducting the...

May 25 2011

BIO commends Reps. Davis (D-Ca) and Schwartz (D-PA) for their continued efforts to extend the...

May 17 2011

BIO today joined the Advanced BioFuel Association, the Renewable Fuel Association, the...

May 11 2011

BIO thanks Rep. Jay Inslee (D-Wash) for introducing the "Domestic Fuel for Enhancing...

May 5 2011

BIO thanks Agriculture Secretary Tom Vilsack and Energy Secretary Steven Chu on the...

May 4 2011

BIO announces selection of Congressman Fred Upton (R-MI) as Legislator of the Year for 2010 -...

May 4 2011

BIO announced today its selection of Senator Bob Casey (D-PA) as Legislator of the Year for...

May 4 2011

BIO announces its selection of Representative David E. Price (D-NC) as Legislator of the Year...

May 4 2011

BIO announces its selection of Michael Capuano (D-MA) as Legislator of the Year for 2010 -...

May 4 2011

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

May 4 2011

Tax incentives that support advanced biofuels, biobased products, and renewable chemicals are...

May 4 2011

BIO thanks Sen. Charles Grassley (R-Iowa) for introducing the Domestic Energy Promotion Act of...

May 3 2011

BIO announces its selection of Senator Patrick Leahy (D-VT) as Legislator of the Year for 2010...

April 28 2011

During BIO's 8th annual World Congress on Industrial Biotechnology and Bioprocessing,...

April 19 2011

Democratic and Republican party leaders and strategists will share their differing...

April 19 2011

The federal Renewable Fuel Standard provides the stable market support and pricing system...

April 15 2011

BIO President and CEO Jim Greenwood releases statement regarding the America Invents Act, H.R...

April 13 2011

According to BIO, the Renewable Fuel Standard provides the market and regulatory certainty...

April 7 2011

Today, the House Subcommittee on Healthcare and Technology will hold a hearing on The Creating...

April 5 2011

The Biotechnology Industry Organization (BIO) hosted a U.S./China Biotechnology Examiner...

March 31 2011

BIO praises House Judiciary Committee Chairman Lamar Smith (R-TX) for his introduction of a...

March 30 2011

BIO thanks President Obama and his administration for leadership in supporting the commercial...

March 8 2011

BIO commends the Senate for its overwhelming passage of the America Invents Act by a vote of...

February 21 2011

The Biotechnology Industry Organization (BIO) stresses the critical importance of protecting...

February 17 2011

BIO welcomes the announcement of the appointment of Teresa Stanek Rea as Deputy Director of...

February 14 2011

Biotechnology Industry Organization (BIO) Industry Analysis and  BioMedTracker (BMT)...

February 9 2011

BIO announces that former Senator John B. Breaux (D-LA), former Member, Senate Finance...

February 8 2011

Since 1995, Pellerito has served as an industry member representative of BIO’s Federal...

February 4 2011

The USDA announces that it will issue a “partial deregulation” for the most...

February 3 2011

BIO appreciates the continued dedication of Chairman Patrick Leahy (D-VT), Ranking Member...

January 28 2011

BIO appreciates the dedication of Chairman Leahy, Ranking Member Charles Grassley (R-IA),...

January 27 2011

The U.S. Department of Agriculture announces that it will fully deregulate a variety of...

January 26 2011

BIO's commends President Obama for highlighting the need to increase our nation...

January 20 2011

BIO thanks Secretary of Agriculture Tom Vilsack for his leadership on biofuels...

January 20 2011

BIO applauds Chairman Lucas (R-Okla.) and Ranking Member Peterson (D-Minn.) for convening...

January 19 2011

 The BioPreferredSM Certified Biobased Product label...

January 13 2011

BIO welcomes the decision by EPA Administrator Lisa Jackson to defer application of CO2...

December 16 2010

Research and development in synthetic biology is an evolution of biotechnology innovation that...

September 29 2010

BIO President and CEO Jim Greenwood released the following statement on action by the U.S....

August 26 2010

Genetically engineered (GE) animals have already realized the promise of advancing human...

March 22 2010

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

March 15 2009

BIO President and CEO Jim Greenwood released the following statement today commending President...

July 30 2008

Small businesses that are majority-backed by venture capital, many of which are producing...

September 21 2007

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

September 19 2007

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

January 11 2007

The recommended improvements to the Prescription Drug User Fee Act (PDUFA) announced today by...

December 13 2006

BIO President and CEO Jim Greenwood today commented on reports that the Securities and Exchange...

July 11 2006

Jim Greenwood issued the following statement in response to the Securities and Exchange...

March 27 2014
February 25, 2013     Marilyn Tavenner, B.S.N., M.H.A. Administrator Centers for Medicare & Medicaid Services Room 445–G, Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201   Re: Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces   Dear Ms. Tavenner:             The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the draft letter related to the Patient Protection and Affordable Care Act’s (ACA) health insurance Marketplaces that the Centers for Medicare & Medicaid Services (CMS) issued on February 4, 2014, entitled “Draft 2015 Letter to Issuers on Federally-facilitated Marketplaces” (the “Draft Letter”).[1]             BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced health care expenditures due to fewer physician office visits, hospitalizations, and surgical interventions. [1] Center for Consumer Information and Insurance Oversight (CCIIO), Centers for Medicare & Medicaid Services (CMS), Draft 2015 Letter to Issuers in the Federally-facilitated Marketplaces (FFM) (Feb. 4, 2014). Available at: http://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/draft-issuer-letter-2-4-2014.pdf (hereinafter “Draft Letter to Issuers”).   
March 27 2014
VIA ELECTRONIC SUBMISSION   March 1, 2014     Patrick Conway, M.D. Deputy Administrator for Innovation and Quality Chief Medical Officer Centers for Medicare & Medicaid Services Center for Medicare and Medicaid Innovation 7500 Security Boulevard Baltimore, MD 21244   RE: Request for Information: Evolution of ACO Initiatives at CMS   Dear Dr. Conway:   The Biotechnology Industry Organization (BIO) is pleased to submit the following comments regarding the Request for Information (RFI) on the “Evolution of ACO Initiatives at CMS” released by the Center for Medicare and Medicaid Innovation (CMMI) on December 20, 2013.[1]  BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations.  BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place.  In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions. [1]           Center for Medicare and Medicaid Innovation, Request for Information: Evolution of ACO Initiatives at CMS (Dec. 20, 2013), available at: http://innovation.cms.gov/Files/x/Pioneer-RFI.pdf.   
December 18 2012
BIO President and CEO Jim Greenwood wrote a letter in support of H.R. 6672, the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2012, sponsored and championed by Chairman Mike Rogers (R-MI).
October 18 2012
A keynote Address by James C. Greenwood, President & CEO of BIO, to RETECH 2012 in Washington, DC on October 18, 2012.
June 28 2012
The U.S. Intellectual Property Rights Attaché Program has had significant success and holds immense promise in helping to enhance IP protection abroad for U.S. interests.
April 9 2014
Consumer-focused legislation will enhance transparency and advance food safety Washington, D.C. (April 9, 2014) – The Biotechnology Industry Organization (BIO), applauds today’s introduction of the Safe and Accurate Food Labeling Act, which would establish a federal standard for the safety and labeling of food and beverage products made with genetically modified ingredients (GMOs).
March 11 2014
BIO commended the Centers for Medicare & Medicaid Services (CMS) for announcing their decision to halt movement on several proposals in their Medicare Part D draft rule.
February 12 2014
Bill would spur capital formation for small public companies
October 28 2013
BIO responds to a Senators letter to FDA Commissioner Margaret Hamburg, regarding naming standards for biosimilars - drugs that are similar to, but not the same as the innovator drugs they seek to replicate.
July 29 2013
BIO released a statement in support of the FDA Safety Over Sequestration Act (H.R. 2725), which would exempt user fees, including those paid by BIO member companies, from the operation of sequestration.